Robeco Institutional Asset Management B.V. Lowers Position in IQVIA Holdings Inc. (NYSE:IQV)

Robeco Institutional Asset Management B.V. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 115,147 shares of the medical research company’s stock after selling 3,247 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in IQVIA were worth $22,628,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in IQV. FMR LLC raised its position in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Impax Asset Management Group plc lifted its stake in shares of IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after purchasing an additional 157,809 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in IQVIA by 3.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after purchasing an additional 39,772 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Up 1.7 %

NYSE:IQV opened at $201.42 on Friday. The company has a market cap of $36.56 billion, a PE ratio of 26.43, a P/E/G ratio of 2.14 and a beta of 1.48. The business’s 50 day moving average is $200.34 and its two-hundred day moving average is $220.78. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Evercore ISI decreased their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Barclays dropped their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Leerink Partners reissued an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.